Immuneering

Immuneering is an oncology-focused company whose scientists developed Deep Cyclic Inhibitors, a new class of medicines designed to pulse faster than cancer's adaptive mechanisms, aiming for more durable tumor control and improved tolerability. The company states that its Deep Cyclic Inhibitors are designed to extend survival and make cancer treatment more tolerable, and that its Deep Cyclic Inhibition platform targets the MAPK pathway, which it says is activated in roughly half of cancers. Its lead Deep Cyclic Inhibitor is atebimetinib. Immuneering was established based on a shared vision to help people with cancer live longer without compromising quality of life during treatment. Ben Zeskind, Ph.D., MBA, has served as Co-Founder, President, Chief Executive Officer and a member of the board of directors since February 2008.

Immuneering was established based on a shared singular vision: to help people with cancer live longer without compromising quality of life during treatment. From the beginning, the company states its mission has remained clear and unwavering: develop therapies that improve survival while preserving the quality of life that matters most to patients and their families. Its scientists developed Deep Cyclic Inhibitors, a new class of medicines designed to pulse faster than cancer's adaptive mechanisms, a rhythmic approach intended to disrupt the tumor's ability to resist treatment while allowing healthy cells to recover between doses. Ben Zeskind, Ph.D., MBA, has served as Co-Founder, President, Chief Executive Officer and a member of the board of directors since February 2008.

Oncology company developing Deep Cyclic Inhibitors designed to disrupt cancer without disrupting life, targeting the MAPK pathway.

• Deep Cyclic Inhibitors

  A new class of medicines designed to pulse faster than cancer's adaptive mechanisms.

• atebimetinib

  Immuneering's lead Deep Cyclic Inhibitor.

1. 1Immuneering | Deep Cyclic Inhibitors for MAPK-Driven Cancersimmuneering.com
2. 2Team | Oncology Drug Development Experts | Immuneeringimmuneering.com
3. 3Our Story | Building a New Standard in Cancer Care | Immuneeringimmuneering.com
4. 4Leadership Team | Oncology Drug Development Experts | Immuneeringimmuneering.com